Eli Lilly and Company LLY

Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. In the trial, which is the largest and longest study of this medicine in type 2 diabetes to date, Foundayo demonstrated a non-inferior risk of major adverse cardiovascular

GLP-1 is a drug platform, not one product. Lilly leads; Novo slips; Pfizer, Amgen, Roche, and AbbVie chase, with pricing, generic and trial risks.

Seven hundred thousand seniors have already started GLP-1s through Medicare, and AstraZeneca just pushed a once-daily pill into late-stage trials. Before you plan your budget around a $50 copay, there are two deadlines that could change everything.

Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market.

Eli Lilly has become one of the market's most closely watched pharma stocks after a very large multi year run, and the question now is whether the cash it can generate in the future really lines up with the price investors are currently paying. With a Discounted Cash Flow (DCF) lens available, the focus turns to the stream of cash flows implied by that rally rather than the headlines alone. Over the past 5 years, Eli Lilly has delivered a return of about 436.8%, which puts a lot of future...

Healthcare stocks declined late Wednesday afternoon with the NYSE Healthcare Index and the State Str

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

People with Type 2 diabetes lost an average of nearly 50 pounds on highest dose of Eli Lilly's GLP-1 medication retatrutide, the company said.

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index easing 0.3% and the S

Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.

Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combination. As Lilly’s stock advanced, shares of primary competitor Novo Nordisk slipped 0.3% on the news.

Roche is increasingly looking like a notable contender in this fast-growing area.